TY - JOUR
T1 - Coverage for Continuous Glucose Monitoring for Individuals with Type 2 Diabetes Treated with Nonintensive Therapies
T2 - An Evidence-Based Approach to Policymaking
AU - Aleppo, Grazia
AU - Hirsch, Irl B.
AU - Parkin, Christopher G.
AU - McGill, Janet
AU - Galindo, Rodolfo
AU - Kruger, Davida F.
AU - Levy, Carol J.
AU - Forlenza, Gregory P.
AU - Umpierrez, Guillermo E.
AU - Grunberger, George
AU - Bergenstal, Richard M.
N1 - Publisher Copyright:
© Grazia Aleppo, et al., 2023.
PY - 2023/10/1
Y1 - 2023/10/1
N2 - Numerous studies have demonstrated the clinical benefits of continuous glucose monitoring (CGM) in individuals with type 1 diabetes (T1D) and type 2 diabetes (T2D) who are treated with intensive insulin regimens. Based on this evidence, CGM is now a standard of care for individuals within these diabetes populations and widely covered by commercial and public insurers. Moreover, recent clinical guidelines from the American Diabetes Association and American Association of Clinical Endocrinology now endorse CGM use in individuals treated with nonintensive insulin regimens. However, despite increasing evidence supporting CGM use for individuals treated with less-intensive insulin therapy or noninsulin medications, insurance coverage is limited or nonexistent. This narrative review reports key findings from recent randomized, observational, and retrospective studies investigating use of CGM in T2D individuals treated with basal insulin only and/or noninsulin therapies and presents an evidence-based rationale for expanding access to CGM within this population.
AB - Numerous studies have demonstrated the clinical benefits of continuous glucose monitoring (CGM) in individuals with type 1 diabetes (T1D) and type 2 diabetes (T2D) who are treated with intensive insulin regimens. Based on this evidence, CGM is now a standard of care for individuals within these diabetes populations and widely covered by commercial and public insurers. Moreover, recent clinical guidelines from the American Diabetes Association and American Association of Clinical Endocrinology now endorse CGM use in individuals treated with nonintensive insulin regimens. However, despite increasing evidence supporting CGM use for individuals treated with less-intensive insulin therapy or noninsulin medications, insurance coverage is limited or nonexistent. This narrative review reports key findings from recent randomized, observational, and retrospective studies investigating use of CGM in T2D individuals treated with basal insulin only and/or noninsulin therapies and presents an evidence-based rationale for expanding access to CGM within this population.
KW - Basal insulin
KW - Continuous glucose monitoring
KW - HbA1c
KW - Noninsulin medications
KW - Type 1 diabetes
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85167890447&partnerID=8YFLogxK
U2 - 10.1089/dia.2023.0268
DO - 10.1089/dia.2023.0268
M3 - Review article
C2 - 37471068
AN - SCOPUS:85167890447
SN - 1520-9156
VL - 25
SP - 741
EP - 751
JO - Diabetes Technology and Therapeutics
JF - Diabetes Technology and Therapeutics
IS - 10
ER -